Overview

Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia

Status:
Recruiting

Trial end date:
2029-10-01

Target enrollment:

Participant gender:

Summary

This is a prospective phase II clinical study to be conducted at the Medical College of Wisconsin. After meeting the study criteria and enrollment, patients will be treated with Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic intervals to determine the primary and secondary objectives.

Phase:

Phase 2

Details

Lead Sponsor:

Medical College of Wisconsin

Treatments:

Cladribine
Cytarabine
Mitoxantrone